Houston Methodist receives $25M gift, renames department of medicine

med funding

Houston Methodist will rename its department of medicine the Houston Methodist Charles W. Duncan Jr. Department of Medicine. Photo courtesy Houston Methodist.

Houston-based nonprofit The Duncan Fund has awarded a $25 million gift to Houston Methodist's department of medicine to establish new endowed fellowships, streamline complex care and bring artificial intelligence into the fold to develop more personalized treatment plans.

In turn, the health care system announced that it will rename the department the Houston Methodist Charles W. Duncan Jr. Department of Medicine.

“We are deeply appreciative of the Duncan family’s support, which allows us to further programs at the intersection of personalized medicine and preventive health care to benefit our patients,” Dr. Eleftherios Mylonakis, chair of the department and the Charles and Anne Duncan Presidential Distinguished Chair, said in a news release.

The department of medicine is Houston Methodist's largest, and comprises 14 clinical programs, ranging from general medicine to highly specialized care, as well as research and education.

According to Houston Methodist, the latest grant from the Duncan family will:

Coordinate complex, multidisciplinary care by hospitalists
Implement programs that leverage data and AI to tailor treatments and preventive strategies
Establish five endowed fellowships, including a new fellowship for students known as MedTech Innovator

“Our vision is to redefine how care is delivered in our country by creating a national model for true continuity — one that follows the patient across every transition, from home to hospital and back again,” Mylonakis added in the release. “We are also advancing a deeper understanding of health span, shifting from reactive treatment to a proactive, lifelong strategy that maximizes not just how long we live but how well we live.”

The Duncan family has been a longtime supporter of Houston Methodist—and Houston organizations at large. The late Charles Duncan Jr. sat on the system's board for decades, and his son, Charles “Carlos” Duncan III, serves on the Houston Methodist Hospital Foundation Board. Additionally, the family established the Charles and Anne Duncan Scholars Program and endowed chairs in nephrology and endocrinology.

Charles Duncan Jr. is also the namesake behind Rice University's Duncan Residential College and was one of the founders of the Greater Houston Partnership. He served as Secretary of Energy during the Carter Administration.

From Your Site Articles

A handful of Houston startups were selected for a national accelerator program. Photo via Getty Images

4 Houston startups selected for preeminent medtech accelerator

ready to grow

Four Houston startups have been selected for the 2023 cohort of the MedTech Innovator’s four-month accelerator program.

Los Angeles-based MedTech Innovator, which bills itself as the world’s largest medtech accelerator, will award $800,000 in funding to winners of its competitions throughout the 2023 program. The grand prize is $350,000.

Almost 1,200 startups applied to participate in this year’s accelerator. From that group, MedTech Innovator, its corporate partners, and more than 400 judges picked nearly 200 candidates for in-person pitching and partnering events. Sixty-one startups ultimately were chosen for the 2023 cohort, which kicks off June 14 and 15.

Forty-two of the 61 startups will participate in MedTech Innovator’s corporate mentorship program, and five companies will join a plastic surgery accelerator in conjunction with the American Society for Plastic Surgeons.

MedTech Innovator says more than 500 startups have completed its accelerator program and have secured $6.8 billion in follow-on funding.

“We are proud of our stellar track record of identifying and perfecting the most innovative medtech startups in the world,” Paul Grand, CEO and founder of MedTech Innovator, says in a news release.

The four Houston companies selected for the MedTech Accelerator’s 2023 cohort are:

Ankr. The startup (whose name is pronounced “anchor”) provides a caregiving platform for cancer patients in the U.S. As of 2022, there were an estimated 18.1 million cancer survivors across the country. The company won The Ion’s Houston Startup Showcase in 2021.
NeuraStasis. The startup is developing an electrical stimulation device to delay the effects of acute ischemic stroke. This type of stroke happens when blood flow to the brain decreases. Acute ischemic stroke affects about 700,000 people in the U.S. each year. The company was selected for last year’s cohort of the UCSF Rosenman Institute’s Rosenman Innovators program.
Nininger Medical. The startup is working on a device for minimally invasive replacement of the tricuspid valve. Today, an estimated 1.6 million Americans experience tricuspid regurgitation. This type of heart disease occurs when the tricuspid valve’s flaps don’t close correctly. In 2021, the company received a $256,000 National Science Foundation grant.
Prana Thoracic. The startup is developing a tool for minimally invasive removal of lung tissue in lung cancer patients. In March, the company announced $3 million in series A funding.

Last year, three Houston companies were selected for the program. The startups — Ad Vital, Corveus Medical, and CorInnova.

Over 1,000 companies applied to participate in the 2023 MedTech Innovator Accelerator, 200 pitched in person, and 61 startups were selected. Graphic via https://medtechinnovator.org/

Three Houston-based health tech companies were announced to have joined the 2022 cohort of MedTech Innovator. Photo via Getty Images

3 Houston health tech companies join global accelerator cohort

Three Houston-based medtech startups are getting a big boost from a medtech accelerator.

The startups — Ad Vital, Corveus Medical, and CorInnova — have been chosen from this year’s cohort for MedTech Innovator, an international accelerator that helps companies that created health care technology. In all, 55 startups are involved in this year’s four-month accelerator program.

Ad Vital and Corveus Medical also are participating in MedTech Innovator’s corporate mentorship program, while CorInnova is one of five startups picked for the pediatric accelerator track.

MedTech Innovator’s 10th annual program kicked off in mid-June at the MedTech Innovator Summit in Mountain View, California. Leaders from each of the 50 startups attended networking events and workshops with MedTech Innovator partners and other industry professionals. Members of this year’s cohort also were featured June 17 at the WSGR Medical Device Conference in San Francisco.

Only 5 percent of applicants were accepted for this year’s accelerator program. Earlier this year, MedTech Innovator held in-person pitch events in five cities, including Houston.

At the conclusion of the 2022 program, MedTech Innovator will award $500,000 in cash and in-kind prizes at this October’s MedTech Conference in Boston. The grand prize is $350,000.

“Over the past nine years, MedTech Innovator has established a unique track record of identifying and supporting leading startups, with 95 percent of our graduates either still in business or having been acquired,” Paul Grand, CEO of MedTech Innovator, says in a news release.

Here’s an overview of what Ad Vital, Corveus Medical, and CorInnova do:

Ad Vital’s app helps medical practices through sales, marketing, and operations. For instance, the app automatically organizes sales campaigns aimed at converting customer leads via text messages, emails, and Facebook messages.
Corveus Medical’s catheter device is designed to prevent heart failure. More than 6 million American adults experience heart failure. The company is also among five selected to pitch in October for a competition from the National Capital Consortium for Pediatric Device Innovation.
CorInnova’s minimally invasive device is engineered to treat congestive heart failure, particularly infants. Each year, about 10,000 babies born in the U.S. have critical heart defects that often require surgery or other procedures.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston neighbor named richest small town in Texas for 2025

Ranking It

Affluent Houston neighbor Bellaire is cashing in as the richest small town in Texas for 2025, according to new study from GoBankingRates.

The report, "The Richest Small Town in Every State," used data from the U.S. Census Bureau's American Community Survey to determine the 50 richest small towns in America based on their median household income.

Of course, Houstonians realize that describing Bellaire as a "small town" is a bit of misnomer. Located less than 10 miles from downtown and fully surrounded by the City of Houston, Bellaire is a wealthy enclave that boasts a population of just over 17,000 residents. These affluent citizens earn a median $236,311 in income every year, which GoBankingRates says is the 11th highest household median income out of all 50 cities included in the report.

The average home in this city is worth over $1.12 million, but Bellaire's lavish residential reputation often attracts properties with multimillion-dollar price tags.

Bellaire also earned a shining 81 livability score for its top quality schools, health and safety, commute times, and more. The livability index, provided by Toronto, Canada-based data analytics and real estate platform AreaVibes, said Bellaire has "an abundance of exceptional local amenities."

"Among these are conveniently located grocery stores, charming coffee shops, diverse dining options and plenty of spacious parks," AreaVibes said. "These local amenities contribute significantly to its overall appeal, ensuring that [residents'] daily needs are met and offering ample opportunities for leisure and recreation."

Earlier in 2025, GoBankingRates ranked Bellaire as the No. 23 wealthiest suburb in America, and it's no stranger to being named on similar lists comparing the richest American cities.

---

This article originally appeared on CultureMap.com.

How a Houston startup is taking on corrosion, a costly climate threat

now streaming

Corrosion is not something most people think about, but for Houston's industrial backbone pipelines, refineries, chemical plants, and water infrastructure, it is a silent and costly threat. Replacing damaged steel and overusing chemicals adds hundreds of millions of tons of carbon emissions every year. Despite the scale of the problem, corrosion detection has barely changed in decades.

In a recent episode of the Energy Tech Startups Podcast, Anwar Sadek, founder and CEO of Corrolytics, explained why the traditional approach is not working and how his team is delivering real-time visibility into one of the most overlooked challenges in the energy transition.

From Lab Insight to Industrial Breakthrough

Anwar began as a researcher studying how metals degrade and how microbes accelerate corrosion. He quickly noticed a major gap. Companies could detect the presence of microorganisms, but they could not tell whether those microbes were actually causing corrosion or how quickly the damage was happening. Most tests required shipping samples to a lab and waiting months for results, long after conditions inside the asset had changed.

That gap inspired Corrolytics' breakthrough. The company developed a portable, real-time electrochemical test that measures microbial corrosion activity directly from fluid samples. No invasive probes. No complex lab work. Just the immediate data operators can act on.

“It is like switching from film to digital photography,” Anwar says. “What used to take months now takes a couple of hours.”

Why Corrosion Matters in Houston's Energy Transition

Houston's energy transition is a blend of innovation and practicality. While the world builds new low-carbon systems, the region still depends on existing industrial infrastructure. Keeping those assets safe, efficient, and emission-conscious is essential.

This is where Corrolytics fits in. Every leak prevented, every pipeline protected, and every unnecessary gallon of biocide avoided reduces emissions and improves operational safety. The company is already seeing interest across oil and gas, petrochemicals, water and wastewater treatment, HVAC, industrial cooling, and biofuels. If fluids move through metal, microbial corrosion can occur, and Corrolytics can detect it.

Because microbes evolve quickly, slow testing methods simply cannot keep up. “By the time a company gets lab results, the environment has changed completely,” Anwar explains. “You cannot manage what you cannot measure.”

A Scientist Steps Into the CEO Role

Anwar did not plan to become a CEO. But through the National Science Foundation's ICorps program, he interviewed more than 300 industry stakeholders. Over 95 percent cited microbial corrosion as a major issue with no effective tool to address it. That validation pushed him to transform his research into a product.

Since then, Corrolytics has moved from prototype to real-world pilots in Brazil and Houston, with early partners already using the technology and some preparing to invest. Along the way, Anwar learned to lead teams, speak the language of industry, and guide the company through challenges. “When things go wrong, and they do, it is the CEO's job to steady the team,” he says.

Why Houston

Relocating to Houston accelerated everything. Customers, partners, advisors, and manufacturing talent are all here. For industrial and energy tech startups, Houston offers an ecosystem built for scale.

What's Next

Corrolytics is preparing for broader pilots, commercial partnerships, and team growth as it continues its fundraising efforts. For anyone focused on asset integrity, emissions reduction, or industrial innovation, this is a company to watch.

Listen to the full conversation with Anwar Sadek on the Energy Tech Startups Podcast to learn more:

---

Energy Tech Startups Podcast is hosted by Jason Ethier and Nada Ahmed. It delves into Houston's pivotal role in the energy transition, spotlighting entrepreneurs and industry leaders shaping a low-carbon future.

This article originally appeared on our sister site, EnergyCapitalHTX.com.

These 50+ Houston scientists rank among world’s most cited

science stars

Fifty-one scientists and professors from Houston-area universities and institutions were named among the most cited in the world for their research in medicine, materials sciences and an array of other fields.

The Clarivate Highly Cited Researchers considers researchers who have authored multiple "Highly Cited Papers" that rank in the top 1percent by citations for their fields in the Web of Science Core Collection. The final list is then determined by other quantitative and qualitative measures by Clarivate's judges to recognize "researchers whose exceptional and community-wide contributions shape the future of science, technology and academia globally."

This year, 6,868 individual researchers from 60 different countries were named to the list. About 38 percent of the researchers are based in the U.S., with China following in second place at about 20 percent.

However, the Chinese Academy of Sciences brought in the most entries, with 258 researchers recognized. Harvard University with 170 researchers and Stanford University with 141 rounded out the top 3.

Looking more locally, the University of Texas at Austin landed among the top 50 institutions for the first time this year, tying for 46th place with the Mayo Clinic and University of Minnesota Twin Cities, each with 27 researchers recognized.

Houston once again had a strong showing on the list, with MD Anderson leading the pack. Below is a list of the Houston-area highly cited researchers and their fields.

UT MD Anderson Cancer Center

Ajani Jaffer (Cross-Field)
James P. Allison (Cross-Field)
Maria E. Cabanillas (Cross-Field)
Boyi Gan (Molecular Biology and Genetics)
Maura L. Gillison (Cross-Field)
David Hong (Cross-Field)
Scott E. Kopetz (Clinical Medicine)
Pranavi Koppula (Cross-Field)
Guang Lei (Cross-Field)
Sattva S. Neelapu (Cross-Field)
Padmanee Sharma (Molecular Biology and Genetics)
Vivek Subbiah (Clinical Medicine)
Jennifer A. Wargo (Molecular Biology and Genetics)
William G. Wierda (Clinical Medicine)
Ignacio I. Wistuba (Clinical Medicine)
Yilei Zhang (Cross-Field)
Li Zhuang (Cross-Field)

Rice University

Pulickel M. Ajayan (Materials Science)
Pedro J. J. Alvarez (Environment and Ecology)
Neva C. Durand (Cross-Field)
Menachem Elimelech (Chemistry and Environment and Ecology)
Zhiwei Fang (Cross-Field)
Naomi J. Halas (Cross-Field)
Jun Lou (Materials Science)
Aditya D. Mohite (Cross-Field)
Peter Nordlander (Cross-Field)
Andreas S. Tolias (Cross-Field)
James M. Tour (Cross-Field)
Robert Vajtai (Cross-Field)
Haotian Wang (Chemistry and Materials Science)
Zhen-Yu Wu (Cross-Field)

Baylor College of Medicine

Nadim J. Ajami (Cross-Field)
Biykem Bozkurt (Clinical Medicine)
Hashem B. El-Serag (Clinical Medicine)
Matthew J. Ellis (Cross-Field)
Richard A. Gibbs (Cross-Field)
Peter H. Jones (Pharmacology and Toxicology)
Sanjay J. Mathew (Cross-Field)
Joseph F. Petrosino (Cross-Field)
Fritz J. Sedlazeck (Biology and Biochemistry)
James Versalovic (Cross-Field)

University of Houston

Zhifeng Ren (Cross-Field)
Yan Yao (Cross-Field)
Yufeng Zhao (Cross-Field)
UT Health Science Center Houston
Hongfang Liu (Cross-Field)
Louise D. McCullough (Cross-Field)
Claudio Soto (Cross-Field)

UTMB Galveston

Erez Lieberman Aiden (Cross-Field)
Pei-Yong Shi (Cross-Field)